Teva Pharmaceutical Industries Limited (TEVA)
NYSE:TEVA
Want to see TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
$32.40
$0.18(0.83%)
At close: 4:00 PM EST
$32.40
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$14.99 - $37.35
Previous CloseN/A
Volume1.13M
Average Volume (3M)6.38M
Market Cap
$40.59B
Enterprise Value$53.74B
Total Cash (Recent Filing)$3.74B
Total Debt (Recent Filing)$16.91B
Price to Earnings (P/E)23.6
Beta0.64
Next Earnings
Aug 05, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.37
Shares Outstanding1,164,638,700
10 Day Avg. Volume4,883,849
30 Day Avg. Volume6,380,627
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.53
Price to Sales (P/S)2.08
P/FCF Ratio31.24
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda16.43
Forecast
1Y Price Target
$42.38Price Target Upside30.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)2.31
Revenue Forecast (FY)$16.57B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Cost EfficiencyManagement focus on reducing leverage and targeting lower net debt, along with encouraging adjusted EBITDA guidance, supports confidence in executing cost-efficiency plans to offset branded-product exclusivity loss.
Clinical EfficacyClinical update shows duvakitug maintained strong efficacy even with extended maintenance dosing intervals, supporting a competitive profile in the TL1a class.
Valuation And Commercial PotentialAnalyst raised valuation after the clinical update to reflect higher expected peak sales for duvakitug, indicating potential for the stock to re-rate as commercial prospects improve.
Bears Say
Competitive Timing RiskPivotal trials for duvakitug are still ongoing and a first-mover competitor is expected to lead market entry, which could limit commercial share and delay uptake.
Margin Outlook RiskConsensus revenue estimates may not fully incorporate margin pressures, creating a risk that earnings could fall short if margins deteriorate more than expected.
Share Price VolatilityShare price volatility driven by macroeconomic factors and ongoing valuation debate increases investment risk and could amplify downside in adverse market conditions.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was $14.99 and its highest was $37.34 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is $40.59B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Aug 05, 2026 which is in 70 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Apr 29, 2026. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.471 by $0.059.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 0.6.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of $0.53 in its last earnings report, beating expectations of $0.471. Following the earnings report the stock price went up 11.891%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.38 (30.79% Upside)
$42.38 (30.79% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 13.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.12%
12-Months-Change
Fundamentals
Return on Equity
20.79%
Trailing 12-Months
Asset Growth
4.23%
Trailing 12-Months
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive strategic and operational picture: strong growth and momentum in the innovative portfolio (AUSTEDO, UZEDY, AJOVY), improving gross margins and cash generation, clear progress on transformation savings and a disciplined, accretive acquisition (Emalex) aligned to the Pivot to Growth strategy. Near-term headwinds include generics comparatives (loss of REVLIMID), accounting and expense impacts from the Emalex asset purchase in 2026, margin reinvestment and some channel/inventory timing uncertainty (notably AUSTEDO destocking and IRA timing). Pipeline milestones present upside but carry binary clinical risk. On balance, the positives — accelerating innovative growth, margin trajectory, balance sheet improvement and clear execution plans — outweigh the near-term and manageable negatives.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$42.38
▲(30.79% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.46% Insiders
7.07% Mutual Funds
35.23% Other Institutional Investors
52.73% Public Companies and Individual Investors